07:00 , Apr 7, 2014 |  BioCentury  |  Finance

1Q Stock Wrap-Up: Small but mighty

Despite a correction at the end of March, all biotech market cap segments finished the first quarter in positive territory. Microcaps set the pace with a 10% gain, while large caps added 7% and were...
07:00 , Mar 31, 2014 |  BC Week In Review  |  Clinical News

Kiobrina: Phase III data

Top-line data from the double-blind, European Phase III LAIF study in 410 preterm infants <32 weeks of gestational age showed that Kiobrina added to preterm formula or pasteurized breast milk missed the primary endpoint of...
07:00 , Mar 31, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Alimera Sciences Inc. (NASDAQ:ALIM) gained $0.60 to $7.20 last week after resubmitting an NDA to FDA for Iluvien fluocinolone acetonide intravitreal implant to treat diabetic macular edema (DME). The company said the resubmission addresses...
00:34 , Mar 27, 2014 |  BC Extra  |  Clinical News

Swedish Orphan falls on Phase III miss for Kiobrina

Swedish Orphan Biovitrum AB (SSE:SOBI) said Kiobrina added to preterm formula or pasteurized breast milk missed the primary endpoint vs. placebo added to preterm formula or pasteurized breast milk in the Phase III LAIF trial...
08:00 , Mar 3, 2014 |  BC Week In Review  |  Clinical News

Kiobrina: Completed Phase III enrollment

Swedish Orphan disclosed in its 2013 financial results that it completed enrollment in a double-blind, placebo-controlled, European Phase III trial evaluating Kiobrina added to preterm formula or pasteurized human milk for 4 weeks in preterm...
07:00 , Apr 9, 2012 |  BC Week In Review  |  Company News

Swedish Orphan Biovitrum deal

Swedish Orphan agreed to settle the remaining development and milestone obligations owed to the former stockholders of Arexis AB, which Swedish Orphan acquired in 2005. Swedish Orphan will pay to the former stockholders SEK77...
07:00 , Aug 8, 2011 |  BC Week In Review  |  Clinical News

Kiobrina: Phase III started

Swedish Orphan began a double-blind, placebo-controlled, European Phase III trial in 70 preterm infants <32 weeks of gestational age to evaluate Kiobrina added to preterm formula or pasteurized human milk for 4 weeks. Swedish Orphan...
07:00 , Jul 12, 2010 |  BC Week In Review  |  Company News

Swedish Orphan Biovitrum, Dongbao deal

The companies signed a letter of intent to form a commercial alliance under which Swedish Orphan would market products from Dongbao in Europe, while Dongbao would market Swedish Orphan's products in China. Products in the...
07:00 , May 10, 2010 |  BC Week In Review  |  Company News

Swedish Orphan Biovitrum deal

Swedish Orphan Biovitrum will make a milestone payment of SEK12.4 million ($1.7 million) through the issuance of 282,425 shares to the former stockholders of Arexis AB. The payment, created under the terms of the...
07:00 , Apr 26, 2010 |  BC Week In Review  |  Clinical News

Kiobrina: Phase II data

Data from a double-blind, crossover, French and Italian Phase II trial in 32 preterm infants showed that Kiobrina delivered in pasteurized breast milk led to improved growth velocity vs. placebo. There were no drug-related serious...